Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331829 | 0.86 | LMNA (0.37) | LMNAPOLBHTTNPC1SMN1; SMN2 | |
| SCHEMBL8295306 | 0.80 | POLB (0.39) | LMNAPOLBHTTNPC1SMN1; SMN2 | |
| SCHEMBL331842 | 0.80 | MEN1 (0.35) | LMNAPOLBHTTNPC1SMN1; SMN2 | |
| SCHEMBL28762839 | 0.79 | POLB (0.36) | LMNAPOLBHTTNPC1SMN1; SMN2 | |
| SCHEMBL332155 | 0.79 | POLB (0.36) | LMNAPOLBHTTNPC1SMN1; SMN2 | |
| SCHEMBL331722 | 0.77 | MEN1 (0.39) | POLBNPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL331635 | 0.75 | MEN1 (0.41) | NPC1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL4705798 | 0.74 | MEN1 (0.46) | POLBSMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL330893 | 0.74 | KMT2A (0.38) | NPC1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL331886 | 0.73 | MEN1 (0.39) | POLBSMN1; SMN2KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689752-B1 | PYRAZOLOPYRIMIDINES | PFIZER LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20070105877-A1 | Pyrazolopyrimidines | PFIZER INC | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105877-A1 | Pyrazolopyrimidines | DPYD, CYP2D6, TPMT | LMNA 4618/4885POLB 598/4885HTT 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.